Gilead Sciences (GILD) Tops Q4 EPS by 17c; Guides
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend
February 2, 2023 4:05 PM ESTFOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the companys Board of Directors has declared an increase of 2.7% in the companys quarterly cash dividend, beginning in the first quarter of 2023. The increase will result in a... More
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results
February 2, 2023 4:01 PM ESTProduct Sales Excluding Veklury Increased Year-Over-Year by 8% for Full Year 2022
Biktarvy Sales Increased Year-Over-Year by 20% for Full Year 2022
Oncology Sales Increased Year-Over-Year by 71% for Full Year 2022
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2022.
2022 marked Gileads strongest full year growth in our base business since HCV sales peaked in 2015. This return to growth was driven by consistent and high quality... More
